Non-Motor Symptoms of Parkinson's Disease: Diagnosis and Management

*Salawu F K FMCP FWACP, *Danburam A FWACP, **Olokoba AB DTMH FWACP

*Department of Medicine, Federal Medical Centre Yola, Nigeria **Department of Medicine, University of Ilorin Teaching Hospital Ilorin, Nigeria

Abstract

**Background:** Non-motor symptoms (NMS) of Parkinson's disease (PD) are a key determinant of health, quality of life (QoL) and societal cost of PD. They are often less appreciated than motor symptoms but are important sources of disability for many PD patients.

**Methods:** Literature search was performed using the reference databases Medline, Science Citation Index and EMBASE. The keywords used were 'non-motor symptoms', Parkinson's disease, olfaction and constipation. Papers discovered by this search were reviewed, as were references cited therein.

**Results:** Contrary to common perception, many NMS of PD occur early in PD and some may even predate the diagnosis of PD that is based on motor signs. These include olfactory deficit, sleep problems such as rapid eye movement behaviour disorder, constipation and the more recently described male erectile dysfunction.

**Conclusion:** There is compelling evidence that non-motor symptoms of PD play a dominant role in the QoL and disability of PD patients and the QoL of their 'informal' carers. Effective clinical management of PD therefore demands that these symptoms be identified and to the extent possible treated.

**Keywords:** Non motor symptoms, Parkinson's disease, Non motor questionnaire, Constipation, Olfaction, male erectile dysfunction

Date Accepted for Publication: 11th January 2010
NigerJMed 2010: 126-131
Copyright © 2010 Nigerian Journal of Medicine

Introduction

Parkinson's disease (PD) is the second most common neurodegenerative disease. Characterized by the cardinal signs of bradykinesia, rigidity, tremor at rest, and abnormalities of balance, posture, and gait, the aetiology of PD remains unknown in most patients. Sir James Parkinson himself recognised Non-motor symptoms (NMS) in PD. Thus, in his essay on the Shaking Palsy in 1817, he referred to sleep disturbance, constipation, urinary incontinence and delirium. NMS in PD, a recognised intrinsic feature of PD, may affect three domains: autonomic, neuropsychiatric, and sensory, including pain. However, despite their impact, the NMS of PD are not well recognised in clinical practise and one study in the United States of America reported that existing depression, anxiety and fatigue are not identified by neurologists in over 50% of consultations, and sleep disturbance in over 40%. Another recent study attempted to correlate NMS in PD at presentation retrospectively after clinico-pathological confirmation of diagnosis. Twenty-one percentage had NMS at presentation and these included pain, anxiety, urinary dysfunction and depression. It is commonly thought that NMS occur only in late or advanced PD but NMS can indeed present at any stage of the disease including early and pre-motor phase of PD. Prospective data based on the Honolulu Asia ageing and other studies suggest that several NMS of PD such as olfactory problems, constipation, depression and erectile dysfunction may predate the motor signs, symptoms and diagnosis of PD by a number of years. These data indicate that NMS may appear early in the course of PD and dominate the later stages of the disease. It has been suggested that some NMS such as olfactory dysfunction in combination with others such as rapid eye movement disorder (RBD) or constipation may form part of a battery of tests to identify a population "at risk of PD", which will be particularly important if and when neuroprotective therapies become available (Table 1).

Stacy and co workers reported that NMS were present even in patients within 5 years of motor disease onset, and these were identified frequently with the use of a patient-completed questionnaire. A comprehensive, self-completed non-motor questionnaire for PD (NMSQuest) was developed to help identify NMS. A range of non-motor symptoms occurred in PD patients from early to advanced disease. The NMSQuest flagged up many NMS such as dribbling of saliva, dysphagia and sexual problems that had not been discussed with a doctor earlier. The study also highlighted that, irrespective of country of study and disease stage, most PD patients are likely to flag up 9 to 12 different NMS in the NMSQuest at clinic visit. Further studies validating the first dedicated scale for
NMS of PD, the PD non-motor scale (NMSS), have indicated a strong relationship between the burden of NMS in PD and health-related QoL. The exact pathophysiology of NMS is still poorly understood. Recent pathological evidence suggests that PD affects the brain in six stages. The first two preclinical are characterized by abnormalities in the olfactory bulb and lower brain stem. Several NMS, including loss of smell, sleep disturbances, and fatigue may occur during these first stages and are preclinical markers of the disease. Tremor, rigidity, and bradykinesia become evident in stages 3 and 4 when the substantia nigra pars compacta is affected. The neocortex and limbic system are affected in stages 5 and 6, which may cause dementia and hallucinations. Screening these early NMS might, therefore, be one approach towards early 'preclinical' diagnosis of PD. This review article provides an overview of the clinical spectrum of NMS in PD together with a brief review of treatment options.

Table I: A list of non-motor symptoms suggested as pre-clinical (motor) features in Parkinson’s disease

| Constipation          |
|-----------------------|
| Olfactory deficit: (discrimination) |
| REM behaviour disorder |
| Depression            |
| Possible links        |
| Restless legs syndrome |
| Apathy                |
| Fatigue               |
| Anxiety               |
| Pain                  |
| Male erectile dysfunction |

**Sleep Disorders**

Sleep disorders affect nearly all PD patients, appear early in the clinical course of PD. They include insomnia, parasomnias, RBD, restless legs syndrome, periodic limb movements of sleep, vivid dreaming, and sleep apnea. In addition, patients may experience disorders of wakefulness, including excessive daytime sleepiness or sudden-onset sleep (sleep attacks) with or without concomitant sleep disorders.

*Excessive daytime sleepiness (EDS)* commonly occurs in PD and frequently adversely affects QoL. EDS can be caused by the disease itself, medications, or sleep disorders. Predictors of EDS in PD include increasing age, advanced disease and higher dosages of dopaminergic medications. Dopamine agonists (DAs) in particular are a common cause of EDS in patients with PD. A careful medication review and sleep history are warranted for patients with EDS. Assessments that can be useful include Parkinson’s Disease Sleep Scale, SCOPA sleep, and Epworth Sleepiness Scale (not specific for PD). If no treatable sleep disorder is identified, treatment with modafinil or other wake-promoting agents can be considered. Several trials have evaluated the use of modafinil, a wake-promoting agent that is approved for use in narcolepsy, for treating EDS in PD. Results of these trials are conflicting and range from modest improvement to lack of efficacy. The dose range of modafinil in these studies was 200 mg/day to 400 mg/day.

**Insomnia** is very common in PD and causes patients to be unable to fall asleep or maintain sleep. It can be treated by having the patient adhere to a consistent sleep schedule, attempt to avoid daytime napping, and abstain from alcohol, caffeine, tobacco and other stimulants in the evening hours. A review of all current medications is warranted to identify those that might be causing insomnia. Depression and anxiety should be treated. Some patients may require the use of hypnotics such as zaleplon or trazadone to treat insomnia.

**REM sleep behaviour disorder (RBD)**

RBD is a parasomnia characterized by loss of normal skeletal muscle atonia during REM sleep when dreaming occurs, leading to “acting out of dreams,” including sleep talking, shouting, and intense, sometimes violent movements. Patients may inadvertently injure their bed partners by punching or choking them. RBD has been reported in 25% to 50% of patients with PD and can precede the onset of PD by several years. Clonazepam can be used in dosages of 0.5 mg to 2 mg at bedtime to treat RBD.

**Restless legs syndrome**

The syndrome of restless legs occur in approximately 20% of patients with PD. It causes patients to experience an urge to move their legs, usually accompanied by uncomfortable leg sensations. It is common in the elderly in Western populations, in which restless legs syndrome affects 8 to 10% of subjects over 65 years of age. DAs, including ropinirole and pramipexole may be used to treat restless legs syndrome in PD. Opioids can also be used but may cause dependency.

**Fatigue**

Fatigue has been reported in 75% PD patients and is more prevalent in patients with PD than in age-matched controls. It is characterized by a feeling of lack of energy with consequent degradation in functional ability and...
Cognitive impairment and dementia

Obstructive sleep apnoea occurs in about 20% of patients with PD and is defined by intermittently absent or reduced airflow during sleep despite respiratory effort. However, patients may not give a history of snoring, and there is a suggestion that PD patients with sleep apnoea need not be obese. Treatment usually consists of wearing an airflow mask, although many patients find it uncomfortable.

Autonomic dysfunction

The prevalence of orthostatic dizziness, constipation, bladder dysfunction, erectile dysfunction, and hyperhidrosis is significantly higher among PD patients than matched controls. Orthostatic hypotension is defined as a drop of 30 mmHg in systolic blood pressure or a drop of 20 mmHg in mean blood pressure when rises to standing from supine position. Orthostatic hypotension and dizziness are associated with an increased risk of falls and resulting fractures. Treatment consists of adequate hydration with eight or more glasses of fluid each day, and the use of mineralocorticoids, such as fludrocortisone, to increase intravascular volume. Other frequently experienced autonomic symptoms in a prospective clinic-based survey of patients with six years of disease duration and more advanced disease were hypersalivation (14%), sexual dysfunction (18%), urinary problems (22%), sweating disorder (24%) and constipation (59%). Potentially useful assessment of autonomic dysfunction include: SCOPA-AUT- a questionnaire to evaluate autonomic dysfunction in PD, QSART- quantitative sudomotor axon reflex for sudomotor function and urodynamics studies for uroflowmetry and cystometry.

Cognitive impairment and dementia

Cognitive impairment may be present even in the early stages of PD. Estimates of the prevalence of cognitive impairment in PD range from 20% to 93% depending probably on how cognitive impairment is defined and assessed. In a community-based survey in early PD, 36% of the patients had evidence of cognitive impairment at diagnosis. The cognitive profile in patients with the disease varies somewhat, but executive impairment, including working memory and attention shift, and visuospatial dysfunction characterize early cognitive impairment in PD. Dementia in PD is associated with longer disease duration and older age at onset and is a risk factor for nursing home placement and is associated with shorter life expectancy. Assessments that can be useful include SCOPA-Cog—a short, reliable instrument sensitive to the specific cognitive deficits in PD and Mini-Mental State Examination (MMSE). Although commonly used to screen for cognitive decline, the MMSE has not been specifically validated in PD and parts requiring a degree of motor skill should probably be discounted. Rivastigmine, a cholinesterase inhibitor, is now approved for use in treating dementia in PD. In a placebo-controlled study, PD patients with mild to moderate dementia were randomly assigned to receive placebo or 3 mg to 12 mg of rivastigmine per day for 24 weeks. Moderate improvements in dementia were noted with rivastigmine use, but there were also higher rates of nausea, vomiting and tremor. Despite the growing literature suggesting benefits of cholinesterase inhibitors therapy, more studies are needed to clarify whether differences exist among the various cholinesterase inhibitors.

Other neurobehavioral disturbances

Neuropsychiatric disorders are important determinants of QoL and caregiver burden in PD. In a population-based study of 139 patients with PD, 61% suffered from at least one neuropsychiatric symptom after 12 years of disease duration. The most common behaviours found were depression (38%) and hallucinations (27%).

Psychotic symptoms in PD (PDPsy) include illusions, the sense of presence, simple and complex hallucinations with and without insight, and delusions. Visual hallucinations are found to be the most common form, while auditory, olfactory and tactile hallucination are less frequent and usually present together with visual hallucination. PDPsy in patients with PD rarely occurred before the introduction of dopaminergic treatment. Dopaminergic agents are therefore understood as an important cause of psychotic symptoms and abnormal behaviour in PD. Reported prevalence rates of hallucination vary, most likely due to differences in patient selection and study design, and range from 16% to 75% in prospective cross-sectional studies. Hallucinations are one of the main features causing hospitalization and nursing home placement in patients with PD.
Depressive symptoms are significantly more common in PD than in age-matched controls and patients with other chronic diseases. They may occur many years before the motor onset of PD. About 20% of patients report depressive symptoms before diagnosis, and the risk for developing PD is 2-3 fold increased in depressed patients compared to non-depressed control subjects. In a recent systematic review of prevalence studies of depression in PD, frequency rates ranged from 12.7% to about 90% in clinical-based studies fulfilling quality criteria for inclusion. This variation is likely to be the result of methodological differences between studies in the studies included. Antidepressants, including tricyclics and selective serotonin reuptake inhibitors (SSRIs) have been found to improve depression in patients with PD, and the DA pramipexole may have antidepressant efficacy.

Olfactory dysfunction
Olfactory dysfunction in PD includes impairment of odour detection, differentiation, and identification, and is persistent and not influenced by drug treatment. In the light of Braak's hypothesis of a stagewise progression of pathological changes in PD, indicating presymptomatic lesions in the olfactory tract, attention has been drawn to patients primarily diagnosed with idiopathic hyposmia. Recent evidence suggests that these persons are at increased risk of developing PD later during life. Olfactory dysfunction is increasingly recognised as a frequent feature in overt PD, but its prevalence in the general PD population is unknown. Most patients showing deficits in olfactory tests are unaware of a smell disorder.

Impulse control disorders
Several complications apparently related to high-dose dopaminergic treatments for PD are comparatively infrequent, but deserve attention because they are socially disabling when they occur. Punding involves compulsive, stereotypical, repetitive and purposeless behaviours that are similar, but distinct from obsessive-compulsive disorder. In a series of 50 patients with higher dopamine replacement therapy (>800 levodopa [L-dopa] equivalent units/day), from 123 unselected PD patients Evans et al identified 17 (14%) patients with punding. Management of punding involves reduction of dopaminergic doses. In a report of three cases, Meseguer reported improvement in all with reduction of dopaminergic doses. There is neither any specific scale nor screening instrument to assess punding nor common diagnostic criteria. Clinicians will need to rely upon interviews as patients with punding appear to be aware of their behaviour but information from caregivers may be most helpful.

Pathological gambling is one of the impulse control disorders that can have disastrous consequences and is related to dopaminergic agonists. In a series of 297 PD patients and using rigorous criteria for impulse control disorders (ICDs), Voon et al found lifetime prevalence of 3% for pathological gambling, 2.4% for pathological hypersexuality and 0.7% for compulsive shopping, giving lifetime prevalence of these ICDs of 6.1%, which increased to 13.7% in patients on dopamine agonists.

Treatment of non-motor symptoms
There is an association between the severity of motor symptoms and the incidence of non-motor symptoms, but the relationship is weak and non-motor symptoms are characteristically unresponsive to L-dopa. Because NMS are generally unresponsive to dopaminergic drugs, clinical management will require interventions commonly used to treat the emergent symptom, but keeping in mind that PD patients are often elderly, at risk for drug-drug interactions and often require doses differing from those for healthy adults.

Summary and conclusions
PD is the second most common neurodegenerative disorder. Non-motor features such as constipation, olfactory dysfunction, depression, anxiety, and sleep disorders may precede the motor onset of the disease. There is compelling evidence the NMS of PD play a dominant role in the QoL and disability of PD patients and the QoL of their 'informal' carers. Effective clinical management of PD therefore demands that these symptoms be identified and to the extent possible, treated. Treatment can be challenging, as these symptoms are often unresponsive to conventional dopaminergic therapy. However, the importance of a multi-professional team-neurologist, specialist nurse, physio- and occupational therapists-is essential for providing optimal care.
References

1. Van Den Eeden SK, Tanner CM, Berstein AL et al. Incidence of Parkinson’s disease: variation by age, gender, and race/ethnicity. Am J Epidemiol 2003; 157: 1015-1022
2. Factor S, Weiner W. Parkinson’s disease. Diagnosis and clinical management. New York: Demos 2002
3. Parkinson J. An essay on the shaking palsy. Sherwood, Neely and Jones, London 1817
4. Shulman LM, Taback RL, Rabinstein AA, Weiner WJ. Non-recognition of depression and other non-motor symptoms of Parkinson’s disease. Parkinsonism Relat Disord 2002; 8: 193-197
5. O’Sullivan SS, Williams DR, Gallagher DA, Massey LA, Silveira-Moriyama L, Lees AJ. Non-motor symptoms as presenting complaints in Parkinson’s disease: a clinicopathological study. Mov Disord 2008; 23: 101-106
6. Chaudhuri KR, Healy D, Schapira AHV et al. The non-motor symptoms of Parkinson’s disease. Diagnosis and management. Lancet Neurology 2006; 5: 235-245
7. Tolosa E, Compta Y, Gaig C. The premotor phase of Parkinson’s disease. Parkinsonism Relat Disord 2007; 13 (Suppl): S2-S7
8. Stacy M, Bowron A, Guttman M, et al. Identification of motor and non-motor wearing off in Parkinson’s disease: comparison of a patient questionnaire versus a clinician assessment. Mov Disord 2005; 20: 726-733
9. Chaudhuri KR, Martinez-Martín P, Schapira AHV et al. International multicentre pilot study of the first comprehensive self-completed non-motor symptoms questionnaire for Parkinson’s disease: The NMSQuest study. Mov Disord 2006; 21: 916-923
10. Chaudhuri KR, Martinez-Martín P, Brown RG et al. The metric properties of a novel non-motor symptoms scale for Parkinson’s disease: results from an international pilot study. Mov Disord 2007; 22: 1901-1911
11. Braak H, Ghebremedhin E, Rub U, et al. Stages in the development of Parkinson’s disease-related pathology. Cell Tissue Res 2004; 38: 121-134
12. Frucht S, Rogers JD, Greene PE, et al. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 1999; 52: 1908-1910
13. Hauser RA, Gauger L, Anderson WM, Zesiewicz TA. Pramipexole-induced somnolence and episodes of daytime sleep. Mov Disord 2000; 15: 658-663
14. Chaudhuri KR, Pal S, DiMarco A et al. The Parkinson’s disease sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinson’s disease. J Neurol Neurosurg Psychiatry 2002; 73: 629-635
15. Marinus J, Visser M, van Hilten JJ et al. Development of a questionnaire for sleep and sleepiness in Parkinson’s disease. Sleep 2003; 26: 1049-1054
16. John MW. Reliability and factor analysis of the Epworth Sleepiness Scale. Sleep 1992; 15: 376-381
17. Adler CH, Caviness JN, Hentz JG et al. Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson’s disease. Mov Disord 2003; 18: 287-293
18. Hauser RA, Wahba MN, Zesiewicz TA, McDowell Anderson W. Modafinil treatment of pramipexole-associated somnolence. Mov Disord 2000; 1269-1271
19. Hogl B, Saletu M, Brandaue E et al. Modafinil for the treatment of daytime sleepiness in Parkinson’s disease: a double-blind, randomized, crossover, placebo-controlled polygraphic trial. Sleep 2002; 25: 905-909
20. Boeve BF, Silber MH, Ferman TJ et al. Association of REM sleep behaviour disorder and neurodegenerative disease may reflect an underlying synucleinopathy. Mov Disord 2001; 16: 622-630
21. Adler CH, Thorpy MJ. Sleep issues in Parkinson’s disease. Neurology 2005; 64: S12-S20
22. Schenck CH, Bundle SR, Mahowald MW. Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder. Neurology 1996; 46: 388-393
23. Onido WW, Dat Vuong G, Khan H et al. Daytime sleepiness and other sleep disorders in Parkinson’s disease. Neurology 2001; 57: 1392-1396
24. Allen RP, Walters AS, Montplaisir J et al. Restless legs syndrome prevalence and impact: REST general population study. Arch Intern Med 2005; 165: 1286-1292
25. Tison F, Crochard A, Leger D, Bouee S, Lainey E, El Hasnaoui A. Epidemiology of restless legs syndrome in French adults: a nationwide survey: the INSTANT Study. Neurology 2005; 65: 239-246
26. Pal PK, Thennarasu K, Fleming J et al. Nocturnal sleep disturbances and daytime dysfunction in patients with Parkinson’s disease and in their caregivers. Parkinsonism Relat Disord 2004; 10: 157-168
27. Brown RG, Dittner A, Findley L, Wessely SC. The Parkinson fatigue scale (PFS-16): the development of a new disease specific instrument for use in research and clinical practice. Parkinsonism Relat Disord 2005; 11: 49-55
28. Herlofson K, Larsen JP. Measuring fatigue in patients with Parkinson’s disease: the fatigue severity scale. Eur J Neurol 2002; 9: 595-600
29. Arnulf I, Konolal E, Merino-Andre M et al. Parkinson’s disease and sleepiness: an integral part of PD. Neurology 2002; 58: 1019-1024
30. Hickler RB, Thompson GR, Fox LM, Hamlin JT 3rd. Successful treatment of orothostatic hypotension with 9-alpha-fluorohydrocortisone. N Engl J Med 1959; 261: 788-791
31. Korchounov A, Kessler KR, Yakhnho NN, Damulin IV, Schipper HI. Determinants of autonomic dysfunction in idiopathic Parkinson’s disease. J Neurol 2002; 252: 1530-1536
32. Visser M, Marinus J, Stiggelbout AM et al. Assessment of autonomic dysfunction in Parkinson’s disease: the SCOPA-AUT. Mov Disord 2004; 19: 1306-1312
33. Foltynie T, Brayne CE, Robbins TW, Barker RA. The cognitive ability of an incident cohort of Parkinson’s patients in the UK. The CamPaIGN study. Brain 2004; 127: 550-560
34. Dubois B, Pillon B. Cognitive deficits in Parkinson’s disease. Neurology 2003; 61: 595-600
35. Emre M. Dementia associated with Parkinson’s disease. Lancet Neurol 2003; 2: 229-237
36. Marinus J, Visser M, Verwey NA et al. Assessment of cognition in Parkinson’s disease. Neurology 2003; 61: 1222-1228
37. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198
38. Emre M, Aarsland D, Albanese A et al. Rivastigmine for dementia associated with Parkinson’s disease. N Engl J Med 2004; 351: 2509-2518
39. Lauterbach EC. The neuropsychiatry of Parkinson’s disease. Minerva Med 2005; 96: 155-173
40. Aarsland D, Larsen JP, Tandberg E, Laake K. Predictors of nursing home replacement in Parkinson’s disease. J Neurol Neurosurg Psychiatry 1999; 67: 492-496
41. de Mainedreville AD, Fenelon G, Mahieux F. Hallucinations in Parkinson’s disease: a follow-up study. Mov Disord 2006; 20: 212-217
42. Fenelon G, Mahieux F, Huon R, Ziegler M. Hallucinations in Parkinson’s disease: prevalence, phenomenology and risk factors. Brain 2000; 123: 733-745
43. Goetz CG, Leurgans S, Pappert EJ, Raman R, Stemer AB. Prospective longitudinal assessment of hallucination in Parkinson’s disease. Neurology 2001; 57: 2078-2082
44. Fenelon G, Goetz CG, Karenberg A. Hallucinations in Parkinson’s disease in the prelevodopa era. Neurology 2006; 66: 93-96
45. Hui MA, Murdock GA, Chung JS, Lew MF. Behavioural changes as side effects of medication treatment for Parkinson’s disease. Adv Neurol 2005; 96: 114-129
46. Aarsland D, Larsen JP, Tandberg E, Laake K. Predictors of nursing home placement in Parkinson’s disease: a population-based, prospective study. J Am Geriatr Soc 2000; 48: 938-942
47. Nilsson FM, Kessing LV, Bolwig TG. Increased risk of developing Parkinson’s disease for patients with major affective disorder: a register study. Acta Psychiatr Scand 2001; 104: 380-386
48. Tandberg E, Larsen JP, Aarsland D, Cummings JL. The occurrence of depression in Parkinson’s disease. A community-based study. Arch Neurol 1996; 53: 175-179
49. Shiba M, Bower JH, Maraganore DM, et al. Anxiety disorders and depressive disorders preceding Parkinson’s disease: a case-control study. Mov Disord 2000; 15: 669-677
50. Leentjens AF, Van den Akker M, Metsemakers JF, Lousberg R, Verhey FR. Higher incidence of depression preceding the onset of Parkinson’s disease: a register study. Mov Disord 2003; 18: 414-418
51. Nilsson FM, Kessing LV, Sorensen TM, Andersen PK, Bolwig TG. Major depressive disorder in Parkinson’s disease: a register-based study. Acta Psychiatr Scand 2002; 106: 202-211
52. Reijnders JS, Ehr U, Weber WE, Aarsland D, Leentjens AF. A systematic review of prevalence studies of depression in Parkinson’s disease. Mov Disord 2008; 23: 183-189
53. Katzschlager R, Zijlmans J, Evans A, Watt H, Lees AJ. Olfactory function distinguishes vascular parkinsonism from Parkinson’s disease. J Neurol Neurosurg Psychiatry 2004; 75: 1749-1752
54. Haehner A, Hummel T, Hummel C, Sommer U, Junghanns S, Reichmann H. Olfactory loss may be a first sign of idiopathic Parkinson’s disease. Mov Disord 2007; 22: 839-842
55. Ross GW, Petrovitch H, Abbott RD et al. Association of olfactory dysfunction with risk for future Parkinson’s disease. Ann Neurol 2008; 63: 167-173
56. Muller A, Reichmann H, Livermore A, Hummel T. Olfactory function in idiopathic Parkinson’s disease (IPD): results from cross-sectional studies in IPD patients and long-term follow-up of de-novo IPD patients. J Neural Transm 2002; 109: 805-811
57. Evans AH, Katzschlager R, Paviour D et al. Punding in Parkinson’s disease: its relation to the dopamine dysregulation syndrome. Mov Disord 2004; 19: 397-405
58. Masegner Gancedo E, Garcia Ruiz PJ. Punding in Parkinson’s disease. Neurologia 2002; 17: 228
59. Voon V, Thomsen T, Miyasaki JM et al. Factors associated with dopaminergic drug-related pathological gambling in Parkinson’s disease. Arch Neurol 2007; 64: 212-216
60. Voon V, Hassan K, Zurowski M et al. Prevalence of repetitive and reward-seeking behaviours in Parkinson’s disease. Neurology 2006; 67: 1254-1237